Coverage
-
June 29, 2018
Actavis Inc. is on its way to settling claims it failed to warn men about risks associated with its drug Androderm as part of multidistrict litigation over testosterone replacement therapy products, according to an order filed Friday.
10 other articles on this case.
View all »